WAVEMAN · COMPANY

OGN · Organon & Co.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

OGN

Name: Organon & Co. (OGN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Organon & Co.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001821825

C-SUITE BUYING · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$200.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

251

13F, latest reported quarter

REVENUE GROWTH

-2.9%

XBRL, annual

NET MARGIN

3.0%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$200.3K over 180 days

-$200.3K over 90 days

more than 51% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

251 funds added or opened last quarter

more than 91% of Pharma & Biotech

REVENUE

-2.9% year over year

below 62% of Pharma & Biotech

MARGIN

3.0% net margin

more than 71% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

6.4% of shares outstanding short · 6.2 days to cover · settled 2026-07-31

more than 62% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

251 funds added or opened positions in the latest 13F quarter, of 634 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +47.4%

+47.4%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $200.3K sold by insiders over 180 days, 251 funds added last quarter, $200.3K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Organon & Co. insiders sold a net $200.3K of stock across 12 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Drinane Juliana Papa

Head of Mfg & Supply

SELL

2026-08-05

14,761.0

$200.3K

Holzbaur Lynette

SVP and Corporate Controller

SELL

2026-05-06

26,448.37

$353.1K

Holzbaur Lynette

SVP and Corporate Controller

BUY

2026-05-06

26,448.37

$353.1K

COX CARRIE SMITH

Executive Chair

BUY

2025-11-12

65,400.0

$501.6K

COX CARRIE SMITH

Director

BUY

2025-05-14

12,469.0

$100.6K

12 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 7 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

32,056,866.0 sh

$434.0M

Pentwater Capital Management LP

18,100,000.0 sh

$245.1M

VANGUARD PORTFOLIO MANAGEMENT LLC

15,132,118.0 sh

$204.9M

VANGUARD CAPITAL MANAGEMENT LLC

11,909,865.0 sh

$161.3M

STATE STREET CORP

9,659,371.0 sh

$130.8M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

JULIANA P DRINANE

FILED 2026-08-05

$200.3K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

First Trust Health Care AlphaDEX Fund

$33.5M POSITION · AS OF 2026-04-30

3.8%

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

$357.2K POSITION · AS OF 2026-04-30

2.8%

Harbor Human Capital Factor US Small Cap ETF

$3.0M POSITION · AS OF 2026-04-30

1.9%

State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF

$5.5M POSITION · AS OF 2026-03-31

1.8%

PROFUND VP PHARMACEUTICALS

$175.3K POSITION · AS OF 2026-03-31

1.7%

Invesco S&P Smallcap 600 Pure Value ETF

$3.0M POSITION · AS OF 2026-04-30

1.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Organon & Co. Employee Political Action Committee

CYCLE 2026 · $63K SPENT

$106.8K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$6.2B	$6.4B	$6.3B	$6.2B
GROSS PROFIT	$3.3B	$3.7B	$3.7B	$3.9B
NET INCOME	$187.0M	$864.0M	$1.0B	$917.0M
EPS (DILUTED)	0.72	3.33	3.99	3.59
OPERATING CASH FLOW	$700.0M	$939.0M	$799.0M	$858.0M
CASH	$574.0M	$675.0M	$693.0M	$706.0M
LONG-TERM DEBT	$8.6B	$8.9B	$8.8B	$8.9B
DIVIDENDS PAID	$88.0M	$297.0M	$294.0M	$290.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE